ONCAlert | Upfront Therapy for mRCC

Ruxolitinib Appears Promising as Treatment of Chronic Graft-Versus-Host Disease

Rushang D. Patel, MD
Published Online: 9:58 PM, Sat February 22, 2020

Rushang D. Patel, MD, of Advent Health in Orlando, Florida, discusses the background to the single center experience with ruxolitinib (Jakafi) as treatment of patients with chronic graft-versus-host disease (GVHD).

There are a number of options in the second-line setting and beyond for chronic GVHD, but the response rates are not as good as clinicians hope. There is always room for better options, Patel says, and there have already been encouraging data for ruxolitinib in acute GVHD, which was approved by the FDA for the third-line setting.

While data from large clinical trials evaluating ruxolitinib in chronic GVHD are maturing, Patel shares his single center experience with ruxolitinib for chronic GVHD in this setting at the 2020 Transplantation & Cellular Therapy Meetings.

<< View more from the 2020 TCT Meetings

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.